Horizon Pharma Inc (HZNP) 29.07 $HZNP
Resilience, Sell Signals Mixed Among Top World Stocks
at Investor's Business Daily - Fri Aug 21, 5:06PM CDT
Commodities and stock markets fighting to adjust to ongoing shifts in global currencies rocked global exchanges for a second day on Friday. Leading stocks were far from exempt as institutional investors trimmed holdings ahead of the rockslide. At the...
AGN: 305.98 (+15.35), NVO: 55.37 (+1.63), CYBR: 50.14 (+3.43), JAZZ: 165.37 (+4.75), HZNP: 29.07 (+1.14), EROS: 31.54 (+0.90), MBLY: 55.30 (+1.72), ICLR: 78.95 (+3.28), AVGO: 116.20 (+7.69)
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (Naproxen/Esomeprazole) Delayed Release Tablets
Marketwired - Thu Aug 20, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced the issuance of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/515,627 (U.S. publication number 2015-0125524), entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" that covers the U.S. approved medicine VIMOVO(R) (naproxen/esomeprazole) delayed release tablets.
HZNP: 29.07 (+1.14), POZN: 8.40 (+0.25)
Depomed's Board of Directors Unanimously Rejects Revised Proposal from Horizon Pharma plc
PR Newswire - Wed Aug 19, 4:35PM CDT
Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company"
today announced that its Board of Directors, after careful consideration and with the assistance of its financial and legal advisors, has unanimously rejected Horizon Pharma plc's (NASDAQ:HZNP) ("Horizon" revised proposal.
HZNP: 29.07 (+1.14), DEPO: 28.40 (+1.00)
Horizon Pharma plc to Amend Preliminary Solicitation Statement to Include Proposed Nominees for Depomed's Board
Marketwired - Wed Aug 19, 1:00PM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it is amending its preliminary solicitation statement filed on Schedule 14A with the Securities and Exchange Commission ("SEC" on August 3, 2015, as amended, to include a proposal to elect individuals whom Horizon Pharma believes should serve as successor directors on the board of directors of Depomed, Inc. ("Depomed" , should Depomed's current board members be removed by shareholders at a special meeting.
HZNP: 29.07 (+1.14), DEPO: 28.40 (+1.00)
Global Gastric Ulcers API Insights 2015-2016
M2 - Mon Aug 17, 4:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ghr4bw/gastric) has announced the addition of the "Gastric Ulcers-API Insights" report to their offering. Gastric Ulcers-API Insights, 2015 report provides Gastric Ulcers drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Gastric Ulcers. The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Gastric Ulcers drugs till 2016. The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China. Companies Mentioned - Santarus, Inc. - Covis Pharmaceuticals, Inc - GlaxoSmithKline Inc. - AstraZeneca PLC - Hanmi USA, Inc. - Horizon Pharma, Inc. - Braintree Laboratories, Inc. - SmithKline Beecham PLC - GlaxoSmithKline plc - Takeda Pharmaceuticals U.S.A., Inc. - AstraZeneca Pharmaceuticals, LP - G. D. Searle, LLC - UCB, Inc. - Merck & Co., Inc. - Perrigo Company For more information visit http://www.researchandmarkets.com/research/ghr4bw/gastric
SNTS: (), PRGO: 183.76 (+5.76), MRK: 54.42 (+3.25), AZN: 31.13 (+0.85), HZNP: 29.07 (+1.14), GSK: 40.47 (+1.06)
Depomed Comments on Horizon Pharma plc Letter
PR Newswire - Thu Aug 13, 1:01PM CDT
Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company" commented on the letter sent today by Horizon Pharma plc (NASDAQ: HZNP) ("Horizon" , in which Horizon has set an exchange ratio of 0.95 of Horizon shares for each share of Depomed, and offered to include up to 25% in cash. Depomed notes that the proposal has a current value below $31 per share,1 which is less than the $33 per share proposal Horizon previously made, and represents ownership in the combined company of less than 29%, which is well below what Depomed would contribute to the combined company.
HZNP: 29.07 (+1.14), DEPO: 28.40 (+1.00)
Horizon Pharma plc Sends Letter to Depomed, Inc Board of Directors
Marketwired - Thu Aug 13, 7:30AM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma" , a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today sent the following letter to the Board of Directors of Depomed, Inc. ("Depomed" .
HZNP: 29.07 (+1.14), DEPO: 28.40 (+1.00)
Investor Alert: Investigation of Depomed Announced by Holzer & Holzer, LLC
Business Wire - Mon Aug 10, 2:58PM CDT
Holzer & Holzer, LLC is investigating whether the board of directors of Depomed, Inc. ("Depomed" or the "Company" (NASDAQ: DEPO) complied with their fiduciary duties in connection with a recent acquisition proposal. Specifically, the firm is investigating whether Depomed's board of directors has responded to Horizon Pharma PLC's communications in accordance with California law.
HZNP: 29.07 (+1.14), DEPO: 28.40 (+1.00)
Company News for August 10, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Mon Aug 10, 9:10AM CDT
Companies in the News are: HZNP,HSY,CST,BR
CST: 34.53 (+0.79), BR: 52.39 (+1.78), HSY: 88.19 (+3.06), HZNP: 29.07 (+1.14)
Horizon Pharma elects George Hampton as EVP of global orphan business unit and international operations
M2 - Mon Aug 10, 3:05AM CDT
Biopharmaceutical company Horizon Pharma (NASDAQ:HZNP) revealed on Friday the appointment of George Hampton as executive vice president of its global orphan business unit and international operations.
HZNP: 29.07 (+1.14)
SHAREHOLDER ALERT: The Wagner Firm Announces Investigation of the Board of Directors of DepoMed, Inc.
Business Wire - Fri Aug 07, 6:59PM CDT
The Wagner Firm announces that it is investigating the board of directors of the DepoMed, Inc. ("DepoMed" (NASDAQ
EPO) concerning possible breaches of fiduciary duty. Specifically, the investigation relates to whether DepoMed's board of directors has failed to adequately consider the recent acquisition proposition from Horizon Pharma PLC. Further, the investigation concerns whether the board of directors has breached their fiduciary duty to shareholders by implementing a poison-pill plan and amending DepoMed's bylaws.
HZNP: 29.07 (+1.14), DEPO: 28.40 (+1.00)
Are 6 Broken Stock Leaders Telling You To Watch Out?
at Investor's Business Daily - Fri Aug 07, 5:43PM CDT
Leading stocks have been getting crushed lately. Is it due to earnings season, or is it a reflection of the broader market? That's the question that many investors may be asking as it seems as if a different firm gets taken down each day. As it turns...
LCI: 50.09 (+3.44), AMCX: 69.72 (+0.46), PGTI: 12.45 (+0.12), HZNP: 29.07 (+1.14), CRTO: 42.42 (+0.80), HRTG: 18.39 (+0.69), AAPL: 109.69 (+5.95)
Horizon Pharma plc Names George Hampton Executive Vice President, Global Orphan Business Unit and International Operations
Marketwired - Fri Aug 07, 3:05PM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today named George Hampton as executive vice president, global orphan business unit and international operations, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective immediately. Hampton has also joined the Horizon's Executive Committee.
HZNP: 29.07 (+1.14)
Horizon Pharma (HZNP) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - Fri Aug 07, 1:12PM CDT
The following Horizon Pharma (HZNP) conference call took place on August 7, 2015, 08:00 AM ET. This is a transcript of that earnings call:
HZNP: 29.07 (+1.14)
Depomed Says Horizon Offered To Raise Bid -- Sort Of
at Investor's Business Daily - Fri Aug 07, 11:46AM CDT
Horizon Pharma (HZNP) stock dipped despite an earnings beat Friday, as Depomed (DEPO) rebuffed another takeover attempt. In a letter to Horizon CEO Timothy Walbert, Depomed CEO James Schoeneck wrote that Walbert had told him Horizon was prepared to...
HZNP: 29.07 (+1.14), DEPO: 28.40 (+1.00)
Losses Growing For Stocks; Monster Bucks Weakness
at Investor's Business Daily - Fri Aug 07, 10:50AM CDT
Stocks worsened and slumped to fresh session lows near midday Friday, as this morning's job data suggested the Fed could be closer to raising interest rates. Hurt largely by biotechs, the Nasdaq fell 0.9%. The S&P 500 and the Dow Jones industrial...
MNST: 138.59 (+4.23), LCI: 50.09 (+3.44), PGTI: 12.45 (+0.12), HZNP: 29.07 (+1.14)
Stocks Stumble Into A Weak Start; Hershey, Horizon Pharma Take Hits
at Investor's Business Daily - Fri Aug 07, 9:35AM CDT
Stocks slumped out of the starting gate Friday as earnings reports roiled early action and an OK July payrolls report dragged mildly on stocks. All three major indexes were down 0.2%. Volume edged up 1% on the Nasdaq and was 17% lower on the NYSE,...
KO: 38.73 (+0.74), ANET: 74.67 (+2.62), MNST: 138.59 (+4.23), HSY: 88.19 (+3.06), HZNP: 29.07 (+1.14), VIAB: 38.61 (+0.03), NVDA: 21.81 (+1.53)
Horizon Pharma (HZNP) Q2 Earnings Up Y/Y, Revenues Beat - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 07, 7:24AM CDT
Horizon Pharma (HZNP) Q2 Earnings Up Y/Y, Revenues Beat
HZNP: 29.07 (+1.14)
Horizon Pharma plc Announces Record Second Quarter 2015 Financial Results
Marketwired - Fri Aug 07, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its second-quarter 2015 financial results today.
HZNP: 29.07 (+1.14)
Depomed Sends Letter to Horizon Pharma
PR Newswire - Fri Aug 07, 5:30AM CDT
Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company" today announced that it has sent the following letter to Horizon Pharma plc (NASDAQ: HZNP) ("Horizon" :
HZNP: 29.07 (+1.14), DEPO: 28.40 (+1.00)
Resilience, Sell Signals Mixed Among Top World Stocks
at Investor's Business Daily - Fri Aug 21, 5:06PM CDT
Commodities and stock markets fighting to adjust to ongoing shifts in global currencies rocked global exchanges for a second day on Friday. Leading stocks were far from exempt as institutional investors trimmed holdings ahead of the rockslide. At the...
AGN: 305.98 (+15.35), NVO: 55.37 (+1.63), CYBR: 50.14 (+3.43), JAZZ: 165.37 (+4.75), HZNP: 29.07 (+1.14), EROS: 31.54 (+0.90), MBLY: 55.30 (+1.72), ICLR: 78.95 (+3.28), AVGO: 116.20 (+7.69)
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (Naproxen/Esomeprazole) Delayed Release Tablets
Marketwired - Thu Aug 20, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced the issuance of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/515,627 (U.S. publication number 2015-0125524), entitled "Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs" that covers the U.S. approved medicine VIMOVO(R) (naproxen/esomeprazole) delayed release tablets.
HZNP: 29.07 (+1.14), POZN: 8.40 (+0.25)
Depomed's Board of Directors Unanimously Rejects Revised Proposal from Horizon Pharma plc
PR Newswire - Wed Aug 19, 4:35PM CDT
Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company"
today announced that its Board of Directors, after careful consideration and with the assistance of its financial and legal advisors, has unanimously rejected Horizon Pharma plc's (NASDAQ:HZNP) ("Horizon" revised proposal. HZNP: 29.07 (+1.14), DEPO: 28.40 (+1.00)
Horizon Pharma plc to Amend Preliminary Solicitation Statement to Include Proposed Nominees for Depomed's Board
Marketwired - Wed Aug 19, 1:00PM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it is amending its preliminary solicitation statement filed on Schedule 14A with the Securities and Exchange Commission ("SEC"
on August 3, 2015, as amended, to include a proposal to elect individuals whom Horizon Pharma believes should serve as successor directors on the board of directors of Depomed, Inc. ("Depomed" , should Depomed's current board members be removed by shareholders at a special meeting. HZNP: 29.07 (+1.14), DEPO: 28.40 (+1.00)
Global Gastric Ulcers API Insights 2015-2016
M2 - Mon Aug 17, 4:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ghr4bw/gastric) has announced the addition of the "Gastric Ulcers-API Insights" report to their offering. Gastric Ulcers-API Insights, 2015 report provides Gastric Ulcers drugs marketed details and API Manufacturers details across the globe along with the location. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the drugs falling under Gastric Ulcers. The Report provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent, patent exclusivity information and competitive landscape. The research analysis also presents the global sales forecasts data for the Gastric Ulcers drugs till 2016. The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing 'Process Validation: General Principles and Practices'. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China. Companies Mentioned - Santarus, Inc. - Covis Pharmaceuticals, Inc - GlaxoSmithKline Inc. - AstraZeneca PLC - Hanmi USA, Inc. - Horizon Pharma, Inc. - Braintree Laboratories, Inc. - SmithKline Beecham PLC - GlaxoSmithKline plc - Takeda Pharmaceuticals U.S.A., Inc. - AstraZeneca Pharmaceuticals, LP - G. D. Searle, LLC - UCB, Inc. - Merck & Co., Inc. - Perrigo Company For more information visit http://www.researchandmarkets.com/research/ghr4bw/gastric
SNTS: (), PRGO: 183.76 (+5.76), MRK: 54.42 (+3.25), AZN: 31.13 (+0.85), HZNP: 29.07 (+1.14), GSK: 40.47 (+1.06)
Depomed Comments on Horizon Pharma plc Letter
PR Newswire - Thu Aug 13, 1:01PM CDT
Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company"
commented on the letter sent today by Horizon Pharma plc (NASDAQ: HZNP) ("Horizon" , in which Horizon has set an exchange ratio of 0.95 of Horizon shares for each share of Depomed, and offered to include up to 25% in cash. Depomed notes that the proposal has a current value below $31 per share,1 which is less than the $33 per share proposal Horizon previously made, and represents ownership in the combined company of less than 29%, which is well below what Depomed would contribute to the combined company. HZNP: 29.07 (+1.14), DEPO: 28.40 (+1.00)
Horizon Pharma plc Sends Letter to Depomed, Inc Board of Directors
Marketwired - Thu Aug 13, 7:30AM CDT
Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma"
, a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today sent the following letter to the Board of Directors of Depomed, Inc. ("Depomed" . HZNP: 29.07 (+1.14), DEPO: 28.40 (+1.00)
Investor Alert: Investigation of Depomed Announced by Holzer & Holzer, LLC
Business Wire - Mon Aug 10, 2:58PM CDT
Holzer & Holzer, LLC is investigating whether the board of directors of Depomed, Inc. ("Depomed" or the "Company"
(NASDAQ: DEPO) complied with their fiduciary duties in connection with a recent acquisition proposal. Specifically, the firm is investigating whether Depomed's board of directors has responded to Horizon Pharma PLC's communications in accordance with California law. HZNP: 29.07 (+1.14), DEPO: 28.40 (+1.00)
Company News for August 10, 2015 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Mon Aug 10, 9:10AM CDT
Companies in the News are: HZNP,HSY,CST,BR
CST: 34.53 (+0.79), BR: 52.39 (+1.78), HSY: 88.19 (+3.06), HZNP: 29.07 (+1.14)
Horizon Pharma elects George Hampton as EVP of global orphan business unit and international operations
M2 - Mon Aug 10, 3:05AM CDT
Biopharmaceutical company Horizon Pharma (NASDAQ:HZNP) revealed on Friday the appointment of George Hampton as executive vice president of its global orphan business unit and international operations.
HZNP: 29.07 (+1.14)
SHAREHOLDER ALERT: The Wagner Firm Announces Investigation of the Board of Directors of DepoMed, Inc.
Business Wire - Fri Aug 07, 6:59PM CDT
The Wagner Firm announces that it is investigating the board of directors of the DepoMed, Inc. ("DepoMed"
(NASDAQ EPO) concerning possible breaches of fiduciary duty. Specifically, the investigation relates to whether DepoMed's board of directors has failed to adequately consider the recent acquisition proposition from Horizon Pharma PLC. Further, the investigation concerns whether the board of directors has breached their fiduciary duty to shareholders by implementing a poison-pill plan and amending DepoMed's bylaws. HZNP: 29.07 (+1.14), DEPO: 28.40 (+1.00)
Are 6 Broken Stock Leaders Telling You To Watch Out?
at Investor's Business Daily - Fri Aug 07, 5:43PM CDT
Leading stocks have been getting crushed lately. Is it due to earnings season, or is it a reflection of the broader market? That's the question that many investors may be asking as it seems as if a different firm gets taken down each day. As it turns...
LCI: 50.09 (+3.44), AMCX: 69.72 (+0.46), PGTI: 12.45 (+0.12), HZNP: 29.07 (+1.14), CRTO: 42.42 (+0.80), HRTG: 18.39 (+0.69), AAPL: 109.69 (+5.95)
Horizon Pharma plc Names George Hampton Executive Vice President, Global Orphan Business Unit and International Operations
Marketwired - Fri Aug 07, 3:05PM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today named George Hampton as executive vice president, global orphan business unit and international operations, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective immediately. Hampton has also joined the Horizon's Executive Committee.
HZNP: 29.07 (+1.14)
Horizon Pharma (HZNP) Earnings Report: Q2 2015 Conference Call Transcript
at The Street - Fri Aug 07, 1:12PM CDT
The following Horizon Pharma (HZNP) conference call took place on August 7, 2015, 08:00 AM ET. This is a transcript of that earnings call:
HZNP: 29.07 (+1.14)
Depomed Says Horizon Offered To Raise Bid -- Sort Of
at Investor's Business Daily - Fri Aug 07, 11:46AM CDT
Horizon Pharma (HZNP) stock dipped despite an earnings beat Friday, as Depomed (DEPO) rebuffed another takeover attempt. In a letter to Horizon CEO Timothy Walbert, Depomed CEO James Schoeneck wrote that Walbert had told him Horizon was prepared to...
HZNP: 29.07 (+1.14), DEPO: 28.40 (+1.00)
Losses Growing For Stocks; Monster Bucks Weakness
at Investor's Business Daily - Fri Aug 07, 10:50AM CDT
Stocks worsened and slumped to fresh session lows near midday Friday, as this morning's job data suggested the Fed could be closer to raising interest rates. Hurt largely by biotechs, the Nasdaq fell 0.9%. The S&P 500 and the Dow Jones industrial...
MNST: 138.59 (+4.23), LCI: 50.09 (+3.44), PGTI: 12.45 (+0.12), HZNP: 29.07 (+1.14)
Stocks Stumble Into A Weak Start; Hershey, Horizon Pharma Take Hits
at Investor's Business Daily - Fri Aug 07, 9:35AM CDT
Stocks slumped out of the starting gate Friday as earnings reports roiled early action and an OK July payrolls report dragged mildly on stocks. All three major indexes were down 0.2%. Volume edged up 1% on the Nasdaq and was 17% lower on the NYSE,...
KO: 38.73 (+0.74), ANET: 74.67 (+2.62), MNST: 138.59 (+4.23), HSY: 88.19 (+3.06), HZNP: 29.07 (+1.14), VIAB: 38.61 (+0.03), NVDA: 21.81 (+1.53)
Horizon Pharma (HZNP) Q2 Earnings Up Y/Y, Revenues Beat - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 07, 7:24AM CDT
Horizon Pharma (HZNP) Q2 Earnings Up Y/Y, Revenues Beat
HZNP: 29.07 (+1.14)
Horizon Pharma plc Announces Record Second Quarter 2015 Financial Results
Marketwired - Fri Aug 07, 6:00AM CDT
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its second-quarter 2015 financial results today.
HZNP: 29.07 (+1.14)
Depomed Sends Letter to Horizon Pharma
PR Newswire - Fri Aug 07, 5:30AM CDT
Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company"
today announced that it has sent the following letter to Horizon Pharma plc (NASDAQ: HZNP) ("Horizon" : HZNP: 29.07 (+1.14), DEPO: 28.40 (+1.00)
